

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Epiworld International Co., Ltd.
瀚天天成电子科技(厦门)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2726)

APPOINTMENT OF CO-GENERAL MANAGER

The board (the “**Board**”) of directors (the “**Director(s)**”) of Epiworld International Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that in accordance with the articles of association of the Company, Dr. Zhao Jianhui (“**Dr. Zhao**”) has been appointed as the co-general manager of the Company with effect from July 17, 2026.

The term of office of Dr. Zhao as the co-general manager of the Company shall commence from July 17, 2026 and shall continue until the expiry of the term of the second session of the Board, and he may be re-elected for consecutive terms.

According to code provision C.2.1 of the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the roles of chairperson of the Board and chief executive officer shall be separate and shall not be performed by the same individual at the same time. Dr. Zhao has been the chairperson of the Board and responsible for the overall strategic planning and operational decisions of the Company for more than ten years and is a seasoned industry player with extensive experience in the industry and corporate management. In view of Dr. Zhao’s experience, personal qualifications and position in the Company, the Board considers that his service as the co-general manager of the Company will be conducive to ensuring the Company’s consistent leadership and more efficient implementation of the Company’s overall strategic plan.

The Board believes that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) any decision to be made by the Board requires approval by at least a majority of the Directors; (ii) Dr. Zhao and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that they act for the benefits and in the best interests of the Company and will make decisions for the Company accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which comprises experienced and high caliber individuals who meet regularly to discuss issues affecting the operations of the Company. Moreover, the overall strategic and other key business, financial, and operational policies of the Company are made collectively after thorough discussions by both the Board and senior management.

The biographical details of Dr. Zhao are set out below:

Dr. Zhao Jianhui (趙建輝), aged 66, is our founder, and was appointed as an executive Director and the chairman of the Board on March 31, 2011. He is mainly responsible for the Company's overall strategic planning and operational decisions.

Dr. Zhao is a renowned scientist with over 35 years of dedicated R&D experiences in SiC technology development. He is the first scientist elected as an IEEE Fellow based on significant contributions to the R&D and application of SiC technologies. After he founded the Company in 2011, he has been serving as our Director and also our chairman of the Board from 2011 to 2012 and since 2014. He has been a chair professor at Xiamen University (廈門大學) in the PRC since December 2021. Between 1988 and 2021, Dr. Zhao served in Rutgers University in the United States.

Dr. Zhao obtained a bachelor of science degree in physics from Xiamen University (廈門大學) in the PRC in July 1982. He received a doctorate degree in electrical and computer engineering from Carnegie Mellon University in May 1988.

The Company has entered into a service contract with Dr. Zhao for his appointment as co-general manager with effect from July 17, 2026. Dr. Zhao will not receive any additional remuneration for serving as the co-general manager of the Company. Dr. Zhao is the spouse of Ms. Pan Menghan, an executive Director. As at the date of this announcement, Dr. Zhao was beneficially interested in 86,814,160 unlisted shares of the Company and 29,746,239 H shares of the Company, representing approximately 20.40% and 6.99% of the issued share capital of the Company, respectively. Dr. Zhao is a cousin of Mr. Li Qinghua (李慶華), who is interested and deemed to be interested in 10.23% of the total share capital of the Company under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

Save as disclosed above, as at the date of this announcement, Dr. Zhao (i) has not held any directorship in any publicly listed companies, whether in Hong Kong or overseas, in the past three years and has no other major appointments and professional qualifications; (ii) does not have any relationship with any director, senior management, substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (iii) does not hold any other positions with the Company and other members of the Group; and (iv) does not have any other interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO. There is no other matter relating to the appointment of Dr. Zhao as the co-general manager that needs to be brought to the attention of the shareholders of the Company, and there is no other matter which is required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

By order of the Board
Epiworld International Co., Ltd.
Dr. Zhao Jianhui
Chairman and Executive Director

Hong Kong, July 17, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhao Jianhui and Ms. Pan Menghan as executive Directors; (ii) Ms. Xie Jieping and Ms. Guo Danxia as non-executive Directors; and (iii) Dr. Kang Junyong, Dr. Liao Yi and Dr. Su Xinlong as independent non-executive Directors.